AAV

Treating Krabbe disease with FBX-101 1:58
Treating Krabbe disease with FBX-101
John Maslowski • 27 Jan 2022
Overcoming immunogenicity of gene therapies 1:16
Overcoming immunogenicity of gene therapies
Timothy Miller • 18 Nov 2021
RESKUE: AAV-based gene therapy for Krabbe disease 0:59
RESKUE: AAV-based gene therapy for Krabbe disease
Timothy Miller • 18 Nov 2021
Increasing manufacturing capabilities for gene therapies 1:58
Increasing manufacturing capabilities for gene therapies
Timothy Miller • 18 Nov 2021
Treating Krabbe disease with AAV-based gene therapies 2:07
Treating Krabbe disease with AAV-based gene therapies
Timothy Miller • 18 Nov 2021
The future of gene therapies for the eye 1:27
The future of gene therapies for the eye
Sue Washer • 22 Oct 2021
Manufacturing challenges in the advanced therapies sector 2:29
Manufacturing challenges in the advanced therapies sector
Sue Washer • 22 Oct 2021
Immunogenicity of AAV-based gene therapies 3:50
Immunogenicity of AAV-based gene therapies
Paul Gissen • 6 Oct 2021
AAV-based gene therapy for X-linked retinitis pigmentosa 2:03
AAV-based gene therapy for X-linked retinitis pigmentosa
Sue Washer • 22 Oct 2021
Optogenetics in advanced retinitis pigmentosa 1:52
Optogenetics in advanced retinitis pigmentosa
Sue Washer • 22 Oct 2021
Treating achromatopsia with AAV-based gene therapy 2:12
Treating achromatopsia with AAV-based gene therapy
Sue Washer • 22 Oct 2021
Enhancing AAV gene therapy in children with inborn errors of metabolism 2:25
Enhancing AAV gene therapy in children with inborn errors of metabolism
Gloria Gonzalez-Aseguinolaza • 18 May 2021
The need for next-gen AAV vectors 1:14
The need for next-gen AAV vectors
Arun Srivastava • 17 May 2021
Synthetic AAV vectors for gene therapy of hemophilia in children 4:15
Synthetic AAV vectors for gene therapy of hemophilia in children
Arun Srivastava • 18 May 2021
The content of VJRegenMed is intended for healthcare professionals